Market Research Report Non-Small Cell Lung Cancer Therapeutics Market | Page 2

In the current market, patients with non-squamous histology can be treated with
more efficacious therapies such as Alimta, while patients harboring activating
mutations in EGFR or ALK can be prescribed targeted therapies such as Tarceva,
Iressa, Gilotrif, Conmana, Xalkori, Alecensa and Zykadia.
Opdivo and Keytruda are mAbs, immune checkpoint inhibitors targeted towards
programmed cell death (PD) 1, and are recent market entrants. The former gained
approval for treating advanced or metastatic squamous NSCLC in Japan in 2015 and
in Australia and South Korea in 2016, and the latter gained approval in Japan in 2016
for the firstand second-line treatment of patients with PD-L1-positive unresectable
advanced/recurrent NSCLC. Tagrisso and Olita EGFR inhibitors that targeted
towards EGFR T790M are also recent market entrants, with the former gaining
approval in Japan, Australia and South Korea, and the latter approved in South Korea
in 2016 for advanced or metastatic patients with EGFR T790M mutation-positive
metastatic NSCLC.
There are currently limited options for patients with squamous cell histology or other
detectable molecular characteristics besides EFGR and ALK mutations. A therapy
that targets mutant KRAS abemaciclib is being developed in the pipeline.
Scope
 The NSCLC Asia-Pacific market will be valued at $6.2 billion in 2023,
growing from $3 billion in 2016 at a CAGR of 10.8%.
 How will immunotherapies such as atezolizumab contribute to growth?
 What effect will patent expirations of currently branded therapies have on
market value?
 The NSCLC pipeline is large and diverse, with an increased presence of mAbs
and targeted therapies.
 What are the common targets and mechanisms of action of pipeline therapies?
 Will the pipeline address unmet needs such as limited treatment options for
squamous cell patients?
 What implications will the increased focus on targeted therapies have on the
future of NSCLC treatment?
 Numerous late-stage pipeline therapies with a strong clinical record have the
potential to enter the market over the forecast period.
 How have the late-stage therapies performed in clinical trials?